Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 501–600 of 1,008
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., & Hallek, M. J. (2002) · Blood · doi:10.1182/blood-2002-01-0288 · Cited by 146
Corcoran, R. B., Settleman, J., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 131
“In general, mechanisms of acquired resistance to targeted therapies commonly employ either mutation or amplification of the drug target itself or alterations which do not involve the drug target but that activate parallel or downstream signaling pathways to circumvent the activity of the drug [23-34].”
BackgroundRegulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression
Reavie, L., Buckley, S. M., Loizou, E., Takeishi, S., Aranda-Orgilles, B., Ndiaye-Lobry, D., Abdel-Wahab, O., Ibrahim, S., Nakayama, K. I., & Aifantis, I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.025 · Cited by 131
“The mechanisms thought to drive resistance and disease relapse include the acquisition of mutations in the kinase domain of Bcr-Abl, amplification of BCR-ABL, and clonal evolution (Gorre et al., 2001; le Coutre et al., 2000; Shah et al., 2002).”
BackgroundKim, T., Tyndel, M. S., Kim, H. J., Ahn, J.-S., Choi, S. H., Park, H. J., Kim, Y.-K., Kim, S. Y., Lipton, J. H., Zhang, Z., et al. (2017) · Blood · doi:10.1182/blood-2016-04-708560 · Cited by 133
“Subtype of TKI therapy, imatinib/2GTKI (%) 78/22 (78:22) 56/18 (76:24) 16/2 (89:11) 6/2 (75:25) Follow-up duration after TKI therapy median (range), mo 55 (3-157) 54 (3-105) 81 (8-157) 39 (5-145)”
Lierman, E., Folens, C., Stover, E. H., Mentens, N., Miegroet, H. V., Scheers, W., Boogaerts, M., Vandenberghe, P., Marynen, P., & Cools, J. (2006) · Blood · doi:10.1182/blood-2006-02-004457 · Cited by 132
Resistance to imatinib mesylate in chronic myeloid leukaemia
Melo, J. V., & Chuah, C. T. H. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.07.010 · Cited by 132
“Secondly, isoleucine contains an extra hydrocarbon group on its side chain and this sterically inhibits the binding of the inhibitor [9].”
BackgroundInfluentialOehler, V. G., Gooley, T. A., Snyder, D., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., et al. (2006) · Blood · doi:10.1182/blood-2006-06-031682 · Cited by 132
The biology of Kit in disease and the application of pharmacogenetics
Akin, C., & Metcalfe, D. D. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.04.046 · Cited by 140
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 129
“majority of patients who respond to imatinib and then experience relapse demonstrate reactivation of the Bcr-Abl tyrosine kinase.(100) At”
BackgroundTargeting Cancer with Small-Molecular-Weight Kinase Inhibitors
Fabbro, D., Cowan-Jacob, S. W., Möbitz, H., & Martiny-Baron, G. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_1 · Cited by 127
Structure and Dynamic Regulation of Abl Kinases*
Panjarian, S. B., Iacob, R. E., Chen, S., Engen, J. R., & Smithgall, T. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.438382 · Cited by 130
Mouse hospital and co-clinical trial project—from bench to bedside
Clohessy, J. G., & Pandolfi, P. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.62 · Cited by 141
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 136
“VEGFR-1/Flt-1 Endothelial cells; some breast and melanoma cancer cells; some leukaemic cells (ATL,CLL) None detected [92-94] VEGFR-2/KDR Endothelial cells; some breast and melanoma cancer cells; some leukaemic cells (CLL) None detected [92,95] PDGFR-α Many cancer cells; tumour stromal cells; leukaemic cells (AML) Ampl…”
BackgroundInfluentialFunctions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy
Noguchi, K., Katayama, K., Mitsuhashi, J., & Sugimoto, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.07.003 · Cited by 143
Rational therapeutic intervention in cancer: kinases as drug targets
Sawyers, C. L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00273-8 · Cited by 138
Self-citationTreatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., & Kolodney, M. S. (2003) · PubMed · Cited by 129
Molecular Basis of Drug Resistance in Aurora Kinases
Girdler, F., Sessa, F., Patercoli, S., Villa, F., Musacchio, A., & Taylor, S. S. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.04.013 · Cited by 128
Synthetic chemistry of pyrimidines and fused pyrimidines: A review
Roopan, S. M., & Sompalle, R. (2016) · Synthetic Communications · doi:10.1080/00397911.2016.1165254 · Cited by 128
“On the other hand, the compounds that contain aniline substituted pyrimidine moiety in their structures were found to be potent anticancer agents and are also reported to exhibit apoptosis-inducing ability.([77,78]) Considering this, researchers synthesized aniline substituted pyrimidine sulfonamide derivatives and sc…”
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Breitenbuecher, F., Markova, B., Kasper, S., Carius, B., Stauder, T., Böhmer, F., Masson, K., Rönnstrand, L., Huber, C., Kindler, T., et al. (2009) · Blood · doi:10.1182/blood-2007-11-126664 · Cited by 128
Ray, A., Cowan‐Jacob, S. W., Manley, P. W., Mestan, J., & Griffin, J. D. (2007) · Blood · doi:10.1182/blood-2006-01-015347 · Cited by 128
Podsypanina, K., Politi, K., Beverly, L. J., & Varmus, H. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801197105 · Cited by 128
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Wendel, H.-G., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J. S., Veach, D. R., Bornmann, W. G., Clarkson, B., McCombie, W. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602402103 · Cited by 124
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era
Wu, P., Langerman, A. J., Ryan, C. W., Hart, J. A. L., Swiger, S., & Posner, M. C. (2003) · Surgery · doi:10.1016/s0039-6060(03)00314-3 · Cited by 126
Tyrosine kinase fusion genes in chronic myeloproliferative diseases
Cross, N. C. P., & Reiter, A. (2002) · Leukemia · doi:10.1038/sj.leu.2402556 · Cited by 126
Huang, M., Dorsey, J. F., Epling‐Burnette, P. K., Nimmanapalli, R., Landowski, T. H., Mora, L. B., Niu, G., Sinibaldi, D., Bai, F., Kraker, A. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206028 · Cited by 145
“However, STI-571 is less effective during the blast crisis of CML and clinical resistance to STI-571 is already beginning to emerge (Druker et al., 2001a; Gorre et al., 2001).”
BackgroundClass effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Giles, F. J., O'Dwyer, M. E., & Swords, R. T. (2009) · Leukemia · doi:10.1038/leu.2009.111 · Cited by 135
The Ins and Outs of Bcr-Abl Inhibition
Reddy, E. P., & Aggarwal, A. K. (2012) · Genes & Cancer · doi:10.1177/1947601912462126 · Cited by 120
Ye, X., Zhu, H., Bai, W., Wang, T., Wang, L., Chen, Y., Yang, A., & Jia, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-134 · Cited by 133
“Trastuzumab resistance of breast cancers can be either cell autonomous or nonautonomous; the latter reflects an extensive interaction between cancer cells and other cells in the microenvironment, including stromal and immune cells [32-34].”
BackgroundBlueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 156
Amarante-Mendes, G. P., Rana, A., Datoguia, T. S., Hamerschlak, N., & Brumatti, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010215 · Cited by 137
Hofmann, W., Komor, M., Waßmann, B., Jones, L. C., Gschaidmeier, H., Hoelzer, D. F., Koeffler, H. P., & Ottmann, O. G. (2003) · Blood · doi:10.1182/blood-2002-06-1756 · Cited by 124
Liao, A. T., Chien, M. B., Shenoy, N., Mendel, D. B., McMahon, G., Cherrington, J. M., & London, C. A. (2002) · Blood · doi:10.1182/blood-2001-12-0350 · Cited by 124
Mathematical Models of Cancer Stem Cells
Michor, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2421 · Cited by 130
Salas, A., Ponnusamy, S., Senkal, C. E., Meyers‐Needham, M., Selvam, S. P., Saddoughi, S. A., Apohan, E., Sentelle, R. D., Smith, C. D., Gault, C. R., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300772 · Cited by 122
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
Harir, N., Boudot, C., Friedbichler, K., Sonneck, K., Kondo, R., Martin-Lannerée, S., Kenner, L., Kerenyi, M., Yahiaoui, S., Gouilleux-Gruart, V., et al. (2008) · Blood · doi:10.1182/blood-2007-09-115477 · Cited by 115
Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells
Kominsky, D. J., Klawitter, J., Brown, J. L., Boros, L. G., Melo, J. V., Eckhardt, S. G., & Serkova, N. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3291 · Cited by 119
Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance
Rochat, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00002 · Cited by 121
Loss of Response to Imatinib: Mechanisms and Management
Shah, N. P. (2005) · Hematology · doi:10.1182/asheducation-2005.1.183 · Cited by 121
Press, R. D., Galderisi, C., Yang, R., Rempfer, C., Willis, S. G., Mauro, M. J., Druker, B. J., & Deininger, M. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1112 · Cited by 126
Stochastic modeling of drug resistance in cancer
Komarova, N. L. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.08.003 · Cited by 120
Evolutionary dynamics of invasion and escape
Iwasa, Y., Michor, F., & Nowak, M. A. (2003) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2003.08.014 · Cited by 132
“For example, resistance to Gleevec is caused by point mutations in the Bcr-Abl oncogene (Gorre et al., 2001; Sawyers, 2001).”
BackgroundSoverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. N., Baccarani, M., the Italian Cooperative Study Group on Chronic Myeloid Leukemia (icsg-cml), et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.031112 · Cited by 120
“Several mutations have been reported in association with the resistant phenotype, and most of them are well characterized in terms of their ability and degree to which they induce resistance (4, 7, 9, 19, 20).”
BackgroundNovel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
Walz, C., & Sattler, M. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.06.007 · Cited by 133
Applying the discovery of the Philadelphia chromosome
Sherbenou, D. W., & Druker, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31988 · Cited by 119
Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R. S., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2007-09-112573 · Cited by 131
Huron, D. R., Gorre, M. E., Kraker, A. J., Sawyers, C. L., Rosen, N. X., & Moasser, M. M. (2003) · PubMed · Cited by 128
Self-citationShi, X., Jin, Y., Cheng, C., Zhang, H., Zou, W., Zheng, Q., Lu, Z., Chen, Q., Lai, Y., & Pan, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2141 · Cited by 115
FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia
Parcells, B. W., Ikeda, A. K., Simms-Waldrip, T. R., Moore, T. B., & Sakamoto, K. M. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0519 · Cited by 134
PTEN is a tumor suppressor in CML stem cells and BCR-ABL–induced leukemias in mice
Peng, C., Chen, Y., Yang, Z., Zhang, H., Osterby, L., Rosmarin, A. G., & Li, S. (2009) · Blood · doi:10.1182/blood-2009-06-228130 · Cited by 123
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
Chand, S. N., O’Hayer, K., Blanco, F. F., Winter, J. M., & Brody, J. R. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14951 · Cited by 129
“, Gleevec giving rise to BCR-Abl mutations) [73].”
BackgroundSignal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 127
SYNTHESIS: Cancer research meets evolutionary biology
Pepper, J. W., Findlay, C. S., Kassen, R., Spencer, S. L., & Maley, C. C. (2009) · Evolutionary Applications · doi:10.1111/j.1752-4571.2008.00063.x · Cited by 118
Blencke, S., Ullrich, A., & Daub, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211158200 · Cited by 114
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Kuroda, J., Kimura, S., Segawa, H., 裕, 小., Yoshikawa, T., Urasaki, Y., Ueda, T., Enjo, F., Tokuda, H., Ottmann, O. G., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0305 · Cited by 122
Francia, S. D., D’Avolio, A., Martino, F., Pirro, E., Baietto, L., Siccardi, M., Simiele, M., Racca, S., Saglio, G. N., Carlo, F. D., et al. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.04.028 · Cited by 116
The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
Cilloni, D., Messa, F., Arruga, F., Defilippi, I., Morotti, A., Messa, E., Carturan, S., Giugliano, E., Pautasso, M., Bracco, E., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403998 · Cited by 123
Steiner, P., Joynes, C., Bassi, R., Wang, S., Tonra, J. R., Hadari, Y. R., & Hicklin, D. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1887 · Cited by 115
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
Druker, B. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206081 · Cited by 130
“This residue was subsequently the first kinase domain mutation described in patients mediating resistance to imatinib (Gorre et al., 2001) and is now known to be one of the most common Abl kinase domain mutations seen in patients who relapse on therapy with imatinib.”
BackgroundStubbs, M. C., Kim, Y., Krivtsov, A. V., Wright, R. D., Feng, Z., Agarwal, J., Kung, A. L., & Armstrong, S. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404951 · Cited by 124
Nishida, T., Kanda, T., Nishitani, A., Takahashi, T., Nakajima, K., Ishikawa, T., & Hirota, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00727.x · Cited by 115
Dai, Y., Rahmani, M., Pei, X., Dent, P., & Grant, S. (2004) · Blood · doi:10.1182/blood-2003-12-4121 · Cited by 124
Mow, B. M. F., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., et al. (2002) · Blood · doi:10.1182/blood.v99.2.664 · Cited by 119
Deshpande, A., Reddy, M. M., Schade, G. O. M., Ray, A., Chowdary, T. K., Griffin, J. D., & Sattler, M. (2011) · Leukemia · doi:10.1038/leu.2011.255 · Cited by 114
“This mutation is homologous to the T315I mutation in BCR-ABL, which causes strong ABL inhibitor resistance in chronic myelogenous leukemia 20, 22 .”
BackgroundKarvela, M., Baquero, P., Kuntz, E. M., Mukhopadhyay, A., Mitchell, R., Allan, E. K., Chan, E. Y. W., Kranc, K. R., Calabretta, B., Salomoni, P., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1162359 · Cited by 118
“However, with time problems of drug resistance and disease persistence have emerged in the clinic.(7,8)”
BackgroundEnteropathogenicEscherichia coliUse Redundant Tyrosine Kinases to Form Actin Pedestals
Swimm, A. I., Bommarius, B., Li, Y., Cheng, D., Reeves, P. M., Sherman, M. A., Veach, D. R., Bornmann, W. G., & Kalman, D. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-02-0093 · Cited by 114
“To develop PD-resistant alleles of Abl and Arg, we took advantage of a mutation in BCR-Abl, T315I, acquired by CML patients who develop resistance to STI-571 (Gorre et al., 2001).”
BackgroundEfficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
Kantarjian, H. M., Larson, R. A., Guilhot, F., O'Brien, S. G., Mone, M., Rudoltz, M., Krahnke, T., Cortes, J., Druker, B. J., & for the International Randomized Study of Interferon and STI571 (IRIS) Investigators (2009) · Cancer · doi:10.1002/cncr.24066 · Cited by 112
“Several of these mechanisms may cause relative resistance to imatinib, which could be overcome with dose escalation.(10,11) However, some mutations may render the disease completely resistant or significantly resistant to imatinib (eg, T315I mutations; or mutations for which the 50% inhibitory concentration of imatini…”
BackgroundFoo, J., & Michor, F. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000557 · Cited by 115
“For example, treatment of chronic myeloid leukemia (CML) with the targeted agent imatinib fails due to acquired point mutations in the BCRABL kinase domain [3].”
BackgroundNelson, E. A., Walker, S. R., Xiang, M. H., Weisberg, E., Bar‐Natan, M., Barrett, R., Liu, S., Kharbanda, S. M., Christie, A. L., Nicolais, M., et al. (2012) · Genes & Cancer · doi:10.1177/1947601912466555 · Cited by 116
“The many years of clinical use of imatinib provides an excellent resource to study the emergence of resistance to tyrosine kinase inhibitors in a clinical setting.(23) Although less is known about resistance to FLT3 inhibitors, resistance to PKC412 has been documented in cell culture models, and these studies have dem…”
Backgroundvon Bubnoff, N. C. C., Peschel, C., & Duyster, J. (2003) · Leukemia · doi:10.1038/sj.leu.2402889 · Cited by 122
Lee, H. J., Thompson, J. E., Wang, E. S., & Wetzler, M. (2010) · Cancer · doi:10.1002/cncr.25690 · Cited by 129
Pathological role of a point mutation (T315I) in BCR‐ABL1 protein—A computational insight
Rajendran, V., Gopalakrishnan, C., & Sethumadhavan, R. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26257 · Cited by 117
“The propensity of residues (1-25) were abridged to form beta-sheets and showed augmented bend conformations due to mutation.”
BackgroundGoldman, J. M., & Gordon, M. Y. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500407996 · Cited by 120
“In practice, resistance is often associated with the finding of expanded Philadelphiapositive clones bearing point mutations coding for amino-acid substitutions in the kinase domain of the Bcr-Abl protein, and more than 30 different mutations have been described [49,50].”
BackgroundBraziel, R. M., Launder, T. M., Druker, B. J., Olson, S. B., Magenis, R. E., Mauro, M. J., Sawyers, C. L., PAQUETTE, R. L., & O'Dwyer, M. E. (2002) · Blood · doi:10.1182/blood.v100.2.435 · Cited by 113
Self-citationMolecular mechanisms of resistance to STI571 in chronic myeloid leukemia
Gorre, M. E., & Sawyers, C. L. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00007 · Cited by 113
Self-citationWang, S., Wang, Y., Xun, X., Zhang, C., Xiao, X., Cheng, Q., Hu, S., Li, Z., & Zhu, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-1523-2 · Cited by 112
Wu, J. Y., Meng, F., Lu, H. Y., Kong, L. Y., Bornmann, W. G., Peng, Z., Talpaz, M., & Donato, N. J. (2008) · Blood · doi:10.1182/blood-2007-08-109330 · Cited by 112
Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2004) · Blood · doi:10.1182/blood-2004-06-2459 · Cited by 112
Wolff, N. C., Richardson, J. A., Egorin, M., & Ilaria, R. L. (2003) · Blood · doi:10.1182/blood-2002-10-3059 · Cited by 111
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells
Wang, Z., Yuan, H., Roth, M., Stark, J. M., Bhatia, R., & Chen, W. Y. (2013) · Oncogene · doi:10.1038/onc.2012.83 · Cited by 109
“4,5 .”
EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler
Sasaki, H., Endo, K., Konishi, A., Takada, M., Kawahara, M., Iuchi, K., Matsumura, A., Okumura, M., Tanaka, H., Kawaguchi, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1904 · Cited by 126
Nimmanapalli, R., O’Bryan, E., Huang, M., Bali, P., Burnette, P. K., Loughran, T. P., Tepperberg, J. H., Jove, R., & Bhalla, K. N. (2002) · PubMed · Cited by 125
Liu, Y., Zhao, G., Xu, C., Luo, Y., Lu, Z.-D., & Wang, J. (2018) · Biomaterials Science · doi:10.1039/c8bm00263k · Cited by 114
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
Villuendas, R., Steegmann, J. L., Pollán, M., Tracey, L., Granda, A., Fernández‐Ruiz, E., Casado, L., Martínez‐López, J., Martinez, P. B., Lombardía, L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404197 · Cited by 111
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Kantarjian, H. M., Giles, F. J., Quintás‐Cardama, A., & Cortes, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2147 · Cited by 121
Al‐Ali, H. K., Heinrich, M. C., Lange, T., Krahl, R., Mueller, M., Müller, C., Niederwieser, D. W., Druker, B. J., & Deininger, M. W. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200319 · Cited by 111
Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Warmuth, M., Damoiseaux, R. D., Liu, Y., Fabbro, D., & Gray, N. S. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454126 · Cited by 119
“Further analysis of patient samples suggested that the mechanisms of resistance are diverse, including gene amplification, point mutations that interfere with STI571 binding, clonal evolution due to secondary mutations and the up-regulation of signalling molecules such as Btk [120-125].”
BackgroundCortes, J. E., Egorin, M. J., Guilhot, F., Molimard, M., & Mahon, F. (2009) · Leukemia · doi:10.1038/leu.2009.88 · Cited by 110
Estrogen receptor mutations and their role in breast cancer progression
Alluri, P. G., Speers, C. W., & Chinnaiyan, A. M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0494-7 · Cited by 120
“imatinib [3] and secondary mutations in epidermal growth factor receptor in nonsmall-cell lung cancer pa-”
BackgroundSTAT5 signaling is required for the efficient induction and maintenance of CML in mice
Ye, D., Wolff, N. C., Li, L., Zhang, S., & Ilaria, R. L. (2006) · Blood · doi:10.1182/blood-2005-10-4110 · Cited by 124
Koenig, H., Holtz, M. S., Modi, H., Manley, P. W., Holyoake, T. L., Forman, S. J., & Bhatia, R. (2008) · Leukemia · doi:10.1038/sj.leu.2405086 · Cited by 111
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00080-6 · Cited by 118
Self-citationImproved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K., Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547760 · Cited by 110
Canning, P., Tan, L., Chu, K., Lee, S. W., Gray, N. S., & Bullock, A. N. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.04.014 · Cited by 100
“In CML, mutation of the gatekeeper Thr315 to Ile confers drug resistance [50], suggesting that an analogous mutation in DDR1 and DDR2 would also confer resistance to imatinib.”
BackgroundHomoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24601 · Cited by 111
“Despite these results, responses in patients with accelerated (AP) or blast phase (BP) CML who receive imatinib, when they occur, are short-lived, and some patients in CP acquire resistance to imatinib, which frequently is associated with point mutations within the kinase domain of BCR-ABL1.(11) A second generation of…”
Eley, T., Luo, F., Agrawal, S., Sanil, A. P., Manning, J., Li, T., Blackwood‐Chirchir, A., & Bertz, R. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333854 · Cited by 113
“Although impressive therapeutic responses have been achieved with imatinib,(2-4) treatment resistance and intolerance are important concerns for the clinician.(5-9) Approximately 12% of patients discontinue imatinib therapy because of either an unsatisfactory response or disease progression.”
BackgroundThe Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 118
“This mutant is analogous to the ABL T315I “gatekeeper” residue substitution that occurs in chronic myeloid leukemia patients in blast crisis phase following an initial response to imatinib treatment.(47) The EGFR T790M mutation in particular has also been shown to decrease EGFR affinity for gefitinib in the context of…”
BackgroundLü, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo, L., Song, N., Bao, X., Chen, P., & Wang, J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138131 · Cited by 109
“…myeloid leukemia or gastrointestinal stromal tumors who underwent therapy with the Bcr-Abl tyrosine kinase inhibitor, imatinib, eventually relapsed due to the appearance of mutations and amplification of the Bcr-Abl gene (Gorre et al., 2001; Mahadevan et al., 2007; Mughal and Goldman, 2007).”
BackgroundMechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review
Yang, K., & Fu, L. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.11.001 · Cited by 109
“[21] Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al.”
BackgroundThe gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity
Emrick, M. A., Lee, T., Starkey, P. J., Mumby, M. C., Resing, K. A., & Ahn, N. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608849103 · Cited by 107
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.